KEYNOTE-100: Final Results From Phase II Study on Pembrolizumab Monotherapy for Advanced Recurrent Ovarian Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Pembrolizumab monotherapy resulted in ORR of 8.5% with median DoR of 10.2 mos and median OS of 18.7 mos in patients with advanced recurrent ovarian cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 321 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Jubilee Brown, MD, and Ursula Matulonis, MD, discuss current challenges in the management of endometrial and ovarian cancer, from Clinical Care Options (CCO)

Jubilee Brown, MD Ursula Matulonis, MD Released: May 3, 2021

From Clinical Care Options (CCO), webcast and downloadable slides on the use of PARP inhibitors to treat ovarian cancer, with Italian subtitles

person default Alexandra Leary, MD, PhD Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci person default Frederik Marmé, MD, PhD Released: April 29, 2021

From Clinical Care Options (CCO), webcast and downloadable slides on the use of PARP inhibitors to treat ovarian cancer, with Spanish subtitles

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
Program Director
person default Alexandra Leary, MD, PhD person default Frederik Marmé, MD, PhD
Released: April 29, 2021

From Clinical Care Options (CCO), webcast and downloadable slides on the use of PARP inhibitors to treat ovarian cancer, with French subtitles

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
Program Director
person default Alexandra Leary, MD, PhD person default Frederik Marmé, MD, PhD
Released: April 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue